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employed to predict the probability of having mania-related
visits in pre-index or post-index period from treatments and 
time ﬁxed-effect, controlling for other covariates. RESULTS: The
ordinary regression indicated a protective effect on mania-related
visits from antidepressant monotherapy compared to mood sta-
bilizer monotherapy (OR = 0.66, 95% CI: 0.49–0.90), without
good control of baseline disease severity. Both propensity score
weighting and matching generated statistically indifferent out-
comes between treatment types. The results of the DD model
identiﬁed a signiﬁcant odds-ratio of 2.40 (95% CI: 1.52–3.79),
suggesting an adverse outcome of increased mania-related visits
with antidepressant monotherapy compared to mood stabilizer
monotherapy. CONCLUSIONS: Ordinary regression, propen-
sity score, and DD methods can produce inconsistent outcomes
when background characteristics are quite different and/or not
all potential confounders can be correctly measured and fully
controlled in the model. DD model may be considered in
outcome studies when pre-and-post data structure is available.
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AN EXPLORATORY STUDY TO DEVELOP A MODEL OF
QUALITY OF LIFE FOR BIPOLAR DISORDER
Doward LC1,Tai SJ2,Taylor JL2
1Galen Research, Manchester, UK; 2University of Manchester,
Manchester, UK
OBJECTIVES: To derive a patient-based model of quality of 
life (QoL) for bipolar disorder (BPD). METHODS: Qualitative
research methods were employed to investigate the impact of
BPD on QoL. Speciﬁcally, to identify how patients perceive their
condition to affect their life quality and how they deﬁne “QoL”.
Semi-structured interviews were conducted with women with a
clinical diagnosis of BPD. Interpretive phenomenological analy-
sis (IPA) was used to explore and interpret participants’ percep-
tions of QoL impact. IPA involves two stages: a case-by-case
thematic analysis, and an interpretive analysis to connect and
cluster themes. For the latter, emphasis was placed on interpret-
ing the meaning and importance ascribed by patients to the
impact of BPD. The data were then compared to existing models
of QoL to derive a QoL model for BPD. RESULTS: As IPA
requires small sample sizes, interviews were conducted with four
women (26–92 (mean 49.5) years). Psychometric tests were
employed to ensure that the women were not currently depressed
(BDI) or manic (SCAN, MRS). Analysis revealed that BPD has
a profound impact on affected individuals. Thematic analysis
identiﬁed key areas of impact including; social life, personal rela-
tionships, self-esteem, work life, fear of rejection and impact on
day-to-day activities. Interpretive analysis revealed eight key the-
matic clusters including; intimate personal relationships, social
impact and personal development/fulﬁllment. Relating these to
existing models of QoL suggested that a needs-based model of
QoL impact was the most appropriate for BPD. The model sug-
gested that areas of need adversely affected by BPD related to;
safety and security, belongingness and love needs; esteem; cog-
nitive needs and self-fulﬁllment. CONCLUSION: BPD impacts
many life areas. Application of IPA revealed that the needs-based
model of QoL can successfully be used to explain the patient’s
perception of, and response to, the symptomatic and functional
impact of the condition.
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TREATMENT ADHERENCE WITH ANTIPSYCHOTICS AMONG
BIPOLAR AND MANIC PATIENTS
Gianfrancesco F1, Rajagopalan K2
1HECON Associates, Montgomery Village, MD, USA; 2AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVE: To assess treatment adherence to antipsychotic
monotherapy in bipolar/manic disorder. METHODS: A total of
18,158 antipsychotic monotherapy treatment episodes for
bipolar and manic disorders were identiﬁed from a claims data-
base (1999–2003) representing 50 million US insured. Adherence
measures included treatment compliance, captured by regularity
of prescription reﬁlls, and treatment duration. Atypicals included
risperidone, olanzapine, quetiapine, and ziprasidone; conven-
tional agents included haloperidol, perphenazine, thioridazine,
and thiothixene. Multiple regression adjusted for patient char-
acteristics. RESULTS: Quetiapine alone had signiﬁcantly (P <
0.05) greater compliance than the conventional agents and had
the highest compliance among the atypicals, which was signiﬁ-
cantly greater than for risperidone or olanzapine. Olanzapine
and ziprasidone demonstrated signiﬁcantly greater compliance
than risperidone. Daily dose was negatively associated with com-
pliance for all agents except quetiapine (P < 0.05 for risperidone
and the conventional agents), which had a positive, but non-
signiﬁcant association (P = 0.074). Quetiapine and risperidone
had signiﬁcantly longer treatment duration than olanzapine,
ziprasidone, and the conventional agents. All atypicals, except
ziprasidone, had signiﬁcantly lower odds of switching to another
psychotropic compared with conventional agents; quetiapine
had the lowest estimated odds ratio. CONCLUSION: Accord-
ing to claims data, treatment adherence for quetiapine ap-
pears higher than for other agents commonly prescribed 




PATTERNS OF DEMENTIA/ALZHEIMER MANAGEMENT
AMONG ELDERLY PATIENTS IN US AMBULATORY CARE
Maneno M,Wutoh A, Jackson P, Lombardo F, Scott K, Xue Z, Lee E
Howard University, Washington DC, DC, USA
OBJECTIVE: To assess patterns of dementia/Alzheimer disease
(AD) management and to investigate predictive factors of 
cognitive-enhancing agents (CEA) use. METHODS: A cross-
sectional study was conducted using 2000–2002 National
Medical Care Survey among elderly patients over the age of 60.
Dementia/AD status was deﬁned according to dementia-related
ICD-9 codes; additionally, patient visit characteristics and CEA
prescriptions associated with dementia/AD status were evaluated
using a logistic regression model. RESULTS: A total of 25,561
patient visit records were identiﬁed. Majority of the visits were
from white patients (90.2%) and approximately half of them
were made by male individuals (45.9%). Of the total visits, only
0.6% (155) had dementia/AD status. Most of the dementia/AD
visits were made by women (60.0%) and persons over the age
of 75 (67.7%). Dementia/AD visit records were predominantly
from white patients (93.5%) and were associated with public
insurance (74.8%; Medicare/Medicaid). Of the dementia/AD
visits, about half (46.5%) were prescribed with one or more CEA
and donepezil HCl was the most prevalent agent that was pre-
scribed (31.6%). Our logistic regression model evaluating pre-
dictive factors of CEA prescription revealed that physician’s
specialty was a strong predictor in the model; as psychiatrists
(OR = 5.5; p < 0.01) and neurologists (OR = 2.6; p < 0.03) were
more likely to prescribe CEA as compared to other physicians.
No other visit characteristics showed signiﬁcant association with
CEA use. CONCLUSION: Early detection and treatment of
dementia delays the progression of cognitive impairment. Con-
sidering the high prevalence of dementia/AD among the elderly
(8–10%) in the US, the study’s results show that dementia man-
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agement in ambulatory care setting is suboptimal as less than
1% of the visits were diagnosed with dementia/AD and only 
half of them had CEA therapy. Additionally our ﬁndings demon-
strate that physicians specialized in psychiatry and neurology
predominantly provide ambulatory care services for dementia
patients.
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OBJECTIVES: Analysis was conducted to estimate annual direct
medical costs for community dwelling persons with dementia
and to determine the proportion of costs in various categories
paid by various payers. METHODS: Retrospective analysis was
conducted of the 2001 Medical Expenditure Panel Survey. The
survey provided data from a sample of 33,556 respondents and
is representative of the civilian non-institutionalized population
of the United States. Dementia patients were identiﬁed using
ICD-9-CM codes. For each patient with dementia, one patient
without dementia was randomly selected matched on age,
gender, race, and number of medical conditions. Medical care
costs for each service component were calculated and compared.
The proportion of medical care costs paid by each payer was 
calculated for dementia patients. Sample estimates were pro-
jected to the population and standard errors were calculated
using the Taylor expansion method. RESULTS: In 2001, the
mean total health care expenditure per patient with dementia
was $12,310, while the mean total expenditure for a matched
patient without dementia was $7300. Among dementia patients,
the highest proportion of costs were for inpatient hospital stays
at $4709 (SE = $727), followed by home health care at $3703
($450). Patients with dementia had a signiﬁcantly higher mean
number of home health provider days at 74.6 days (10.5), com-
pared to patients without dementia, 3.8 days (1.0). The major
sources of payments for health care expenditures of dementia
patients were Medicare (38.3%) and out-of-pocket payments
(32.6%). Approximately 62% of prescription drug expenditures
among dementia patients were paid out-of-pocket. Incremental
costs per patient with dementia were $5010, or a total cost 
of $8.3 billion attributable to dementia in community dwelling
patients. CONCLUSIONS: Community dwelling dementia
patients cost approximately 1.7 times more than similar patients
without dementia. A high proportion of total expenditures, espe-
cially prescription drug expenditures among dementia patients
were paid out-of-pocket.
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OBJECTIVES: Poorer health related quality of life (HRQOL)
has been observed among dementia caregivers relative to the
general population. However, the temporal stability of and
factors associated with caregiver HRQOL have been little
studied. METHODS: Dementia caregivers were randomized to
one of two treatment arms: a multi-component, psychosocial
intervention aimed at increasing social support (n = 69) or to 
a usual care, control group (n = 65). Caregiver HRQOL was
assessed over a two-year period using a Visual Analogue Scale
(VAS), the Health Utilities Index Mark III (HUI), and the SF-36
(physical health [PCS] and mental health [MCS] summary
scores). Patient-speciﬁc and caregiver-speciﬁc data were collected
every four-months during the ﬁrst year and every six-months
thereafter. A step-wise, mixed-model approach was employed to
assess the association of treatment-, patient-, and caregiver-
speciﬁc variables to caregiver HRQOL. RESULTS: None of the
patient demographic variables was associated with caregiver
HRQOL. Caregiver gender, health status and depression along
with patient dementia severity were all inversely associated with
the VAS, but patient nursing home placement was positively
associated. Caregiver age, health status and depression were
inversely associated with the HUI. Dementia severity and care-
giver depression were inversely associated with the MCS. Care-
giver age and health status were inversely associated with the
PCS. Time since enrollment was positively associated with care-
giver MCS but inversely associated with caregiver PCS; time was
not signiﬁcantly associated with the VAS or HUI. CONCLU-
SIONS: A number of patient-, caregiver-, and time-related vari-
ables were differentially associated with the disparate measures
of HRQOL. Caregiver depression and health status are consis-
tently associated with poorer HRQOL regardless of instrument
used to measure it. The VAS and HUI appear to be more stable
measures of HRQOL than the summary scores from the SF-36.
However, small sample size and methodological limitations
temper these ﬁndings.
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OBJECTIVE: This analysis was designed to compare improve-
ments in health-related quality of life (HRQoL) measured by the
General Life Functioning scale (GLF) in patients with major
depressive disorder (MDD) treated with venlafaxine extended
release (XR), sertraline, or placebo. METHODS: Data were
pooled from two identical multicenter, randomized, double-
blind, placebo-controlled studies of ﬂexible-dose venlafaxine XR
(37.5–300mg/day) and sertraline (50–200mg/day) in 10-week
treatment of DSM-IV MDD (N = 1352). Average per-item score
(ranging from one being “best” and six being “worst”) of overall
GLF and its three subscales (well-being, coping, and closeness)
were used to assess functioning. Improvement was measured by
reduction from baseline score at the end of the study, and was
analyzed using ANCOVA controlling for study center and base-
line values. In addition, the overall trend of weekly scores during
treatment was evaluated using repeated measures mixed model.
RESULTS: At baseline, GLF per-item score had a median of four.
At the end of study, venlafaxine XR was associated with signif-
icant (P < 0.0001) improvement (as measured by per-item score
reduction from baseline) compared with placebo on GLF total
score (1.0 vs. 0.6) and all three subscales: well-being (1.2 vs. 0.7),
coping (1.0 vs. 0.6), and closeness (0.8 vs. 0.4). The weekly
trends of total and subscale scores were also signiﬁcantly better
for venlafaxine XR compared with placebo (all P < 0.0025). Ser-
traline/placebo differences on all measures were also statistically
signiﬁcant but numerically smaller. CONCLUSION: Venlafaxine
XR and sertraline treatment were associated with signiﬁcant
improvement on HRQoL measured by GLF in depressed
patients.
